At TMCx's Demo Day, the cohort's companies boasted of local deals and accomplishments. Courtesy of TMC

At the conclusion of TMCx's recent Digital Health cohort — the most international group to date — there was only one Houston company among the 19. However, most of that group have developed a presence in Houston throughout the program.

Besides just being based here in Houston for four months, TMCx associate director, Lance Black, says the city has a lot to offer these startups.

"Why Houston? Why are these companies coming from everywhere to be here? Three big reasons," he says to the crowd at Demo Day. "The size and scale of the Texas Medical Center, the diversity of Houston, and the willingness and hunger of Houstonians wanting to be involved in innovation."

From pilots and partnerships to funding and mentorship, these TMCx08 companies announced the impact they've made on Houston at the Demo Day on Thursday, June 6. Meanwhile, TMCx had its own announcement that it would create early stage programming for professionals connected to the Texas Medical Center.

"It is the TMC's mission to advance health care, research, and education. It's our mission at the Innovation Institute to bring value back to the med center through health care technology," Black says. "And, through TMCx, we do that through startup companies."

Here are some examples of TMCx companies setting foundations in the Houston ecosystem.

Virti

Photo via virti.com

California-based Virti has developed an extended reality simulation technology for training medical staff. It's a cheaper, more effective way to train personnel, says Alex Young, CEO of the company.

Virti was selected to be in England's National Health Service accelerator — the only evidence-based AR/VR training company ever to be picked for the program, says Young.

With a presence in California and England, Young says he's also planted roots in Texas too, with sales representation based in the TMCx offices.

"In the time that we've been here, we've closed deals in Texas and back in California," Young adds.

Optellum

Photo via optellum.com

Optellum is changing the way lung cancer is being detected. With the startup's artificial intelligence-enabled detection software, oncologists can better identify at-risk patients, which translates into more treatment for those in need, and less for those who don't.

The company, which is based in the United Kingdom, has raised funds abroad while networking locally.

"TMCx has been amazing for a small British company like us. We have started pilots and trials at four TMC member institutions," says Vaclav Potesil, CEO.

Oncora Medical

Photo via oncoramedical.com

Angela Holmes, the director of product and customer solutions of Oncora Medical, sets the stage at her company's Demo Day pitch by telling a story of her friend's daughter who was diagnosed with cancer. She was forced to pick between two treatment options. She had no data or insights to help.

Oncora Medical's mission is to help fight cancer using data. Though based in Philadelphia, Oncora has Houston ties, since it formed a partnership with MD Anderson Cancer Center in April of 2017.

"We are so honored and gratified to be in a strategic, multi-year collaboration with MD Anderson to build this software system to save the world," Holmes says.

PreOp MD

Cody Duty/TMC

Within health care, the projected annual aggregate surgical expenditure by 2025 is expected to be $912 billion, says Christiana Obi, founder and CEO of PreOp MD, and a Houston-based anesthesiologist. She sees lack of information causing wasted surgical resources regularly.

PreOp MD — the only Houston-based TMCx company this cohort — has an app that allows for pre-procedure education, communication, and more that aims to prevent surgical delays.

While based here, PreOp is truly rooted in Houston, and even more so with their latest news.

"We are happy and excited to say that we have landed our first medical pilot at an medical right here in town," Obi says.

RoundTrip

Cody Duty/TMC

RoundTrip has a solution to 3.6 million missed or postponed medical visits that happen annually that are inconvenient to hospitals and a major health risk to the population: Ride sharing.

The Philadelphia-based company enables all forms of transportation and puts the power in the hands of the medical institution. From ambulances to other medical vehicles, the company can optimize utilization of all vehicles to get patients to their appointments and even has a partnership with Lyft.

While completing the TMCx program, RoundTrip closed its Series A round of $5.14 million led by Virginia-based Motley Fool Ventures in April. The funds will be used for expansion.

"Now we have all this new money to expand really rapidly. Texas, we're coming for you, whether you're ready or not," says Jackson Steeger, account supervisor.

Meru Health

Photos via meruhealth.com

Meru Health is also one of the 2019 TMCx Digital Health companies that has raised money while in the program. Palo Alto, California-based Meru completed a $4.2M raise in April 2019. The round was led by San Francisco-based Freestyle Capital.

Access to mental health professionals is increasingly more difficult, so Meru Health has created a low-cost digital clinic that offers an app-based treatment program from licensed therapists. Kristian Ranta, CEO and founder, while not yet providing specifics, that they aren't done in Texas.

"I'm happy to say there's some good stuff brewing here in Texas for us. More to follow," says Ranta.

Cloud 9

Photo via cloud9psych.com

Mental health is a key contributing factor in the legal system cycle, but it doesn't have to be Liz Truong, co-founder of Cloud 9. Better educating officers and providing them with mental health resources is the best way to get them out of the hospitals and court rooms and back out in the field to protect the city.

While some police departments have instituted ride-along programs with mental health professionals that have showed success, it's expensive for the police department and risky for those professionals. Cloud 9 has created a digital solution.

"We proved this works in the Harris County Sheriff's office right here in Houston," says Truong. "Officers reported that 97 percent of Cloud 9 care was superior or equal to their current program and showed an immediate 632 percent return on investment for our customers in the same budget cycle compared to what they were already spending."

Truong also says they have other local customers they are working with, including the Harris County Health Department.

Axem Neurotechnology

Photos via axemneuro.com

Recovering stroke patients need rehabilitation to get back to 100 percent, but getting patients into the facility is challenging and at-home compliance is hard to track.

Canadian company Axem Neurotechnology has a solution. With their external device and mobile application, physical therapists can track progress and communicate with patients remotely.

"When we talk to rehab professionals, they are excited about what we're doing," says Tony Ingram, CEO and co-founder. "That's why we have leading institutions in both Canada and the U.S. onboard for clinical trials — this includes TMC's own TIRR, which is consistently ranked in the top five rehab centers in the U.S. We're collecting core baseline data in the most diverse city in the country."


Correction: A previous version of this article said Oncora's partnership with MD Anderson was formed during the TMCx program, when the partnership began in 2017.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.

Axiom Space launches Japanese subsidiary, names leadership

Axiom Space is setting up a Japanese subsidiary to tap into billions of dollars worth of business opportunities in the vast Asia-Pacific region. The company’s new office in Japan will open July 1.

“For the Asia-Pacific region, an Axiom Space presence in Japan means a long-term, direct path to low-Earth orbit for research, for industry, for astronauts, and a partner committed to building that future together with Japan,” Jonathan Cirtain, president and CEO of Axiom Space, said in a news release.

Asia-Pacific spaceflight leaders include Japan, China, India and South Korea.

Until committing to the Asia-Pacific subsidiary, Axiom focused primarily on the U.S. market for space exploration equipment, technology and services. Axiom is building the successor to the International Space Station (ISS), and it provides human spaceflight services and develops next-generation spacesuits.

Fortune Business Insights estimates the Asia-Pacific market for space technology was valued at $155.3 billion in 2025.

“The region is rapidly expanding due to rapidly expanding government space programs, increasing private sector participation, and rising demand for satellite services across densely populated regions,” says Fortune Business Insights, a market research firm.

The region’s combination of strategic investments, market demand and emerging entrepreneurial systems positions Asia-Pacific “for the fastest growth in the global market,” Fortune Business Insights says.

The market research firm pegs the U.S. market for space technology at $251.8 billion in 2025, making it the world’s largest player in that sector.

Veteran Japanese astronaut Koichi Wakata will lead Axiom Space Japan as chief technology officer in the Asia-Pacific region. The Japanese subsidiary will work with government agencies, research institutions, and industrial partners in Japan to expand hardware development and manufacturing, microgravity research and orbital computing.

Wakata was the Japanese space agency’s first program manager for ISS and the station’s first Japanese commander. He also contributed to the construction of ISS, including the Japanese experiment module Kibo. Wakata retired from the Japanese agency, JAXA, in March 2024.

“Japan intends to remain a leading nation in human space exploration post-ISS, and Japanese industry and academia are ready to play a central role in the commercial era,” Axiom Space said in the release. “Axiom Space Japan is how the company will meet that ambition with a long-term, on-the-ground presence.”

Houston investment firm closes $105M energy venture fund

seeing green

Houston-based investment firm Veriten has announced the initial close of its second flagship energy venture fund with more than $105 million in capital commitments.

Fund II will build on Veriten’s initial fund and aim to support “scalable technology solutions for energy, power and industrial applications,” according to a company news release.

"Our differentiated network, research-driven process, and first principles approach to investing are having an impact across multiple verticals including traditional energy, electrification, and industrial technology. Fund II builds on that platform,” John Sommers, partner, investments at Veriten, added in the release. “In this environment, the differentiator isn't capital – it's all about connectivity, deep sector expertise, and an economically-driven approach. As new technologies and approaches develop at breakneck speed, the need for more reliable, affordable energy and power continues to grow dramatically. The current backdrop accentuates the need for Veriten's solution."

Veriten is supported by over 50 strategic partnerships in the energy, power, industrial and technology sectors, including major players like Halliburton and Phillips 66.

"Veriten continues to build a differentiated platform at the intersection of energy, technology and industry expertise," Jeff Miller, chairman and CEO of Halliburton, said in the release. "We were early believers in the team and their ability to identify practical solutions to real challenges across the energy value chain. As all industries increasingly adopt digital tools, automation and AI-enabled technologies to improve performance and execution, we are proud to partner with Veriten again to help accelerate high-impact solutions across the broader energy landscape."

Veriten closed its debut fund, NexTen LP, of $85 million in committed capital in October 2023. It was launched in January 2022 by Maynard Holt, co-founder and former CEO of the energy investment bank Tudor, Pickering, Holt & Co.

It has invested in Houston-based AI-powered electricity analytics provider Amperon and led a $12 million Seed 2 funding round for Houston-based Helix Technologies to scale manufacturing of its energy-efficient commercial HVAC add-on earlier this year. In the past year it has contributed to funding rounds for San Francisco-based Armada and Calgary-based Veerum.

Veriten also named Nick Morriss as its new managing director earlier this month. Morriss most recently served as vice president of business development at next-generation nuclear technology company Natura Resources and spent nearly 20 years at NOV Inc.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.